Leptomeningeal metastasis: challenges in diagnosis and treatment

T Leal, JE Chang, M Mehta… - Current cancer therapy …, 2011 - ingentaconnect.com
As therapeutic options and supportive care for the treatment of neoplastic disease have
improved, there has been an associated increase in the incidence of leptomeningeal …

[HTML][HTML] Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%

M Reck, D Rodríguez-Abreu, AG Robinson… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell
Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% - PMC Back to Top Skip to main …

Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology

DS Ettinger, DE Wood, DL Aisner, W Akerley… - Journal of the National …, 2017 - jnccn.org
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

[HTML][HTML] Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

R Yaeger, J Weiss, MS Pelster, AI Spira… - … England Journal of …, 2023 - Mass Medical Soc
Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …

NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines

DS Ettinger, DE Wood, DL Aisner, W Akerley… - Journal of the National …, 2021 - jnccn.org
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 in: Journal of the
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …

[HTML][HTML] Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and …

SV Liu, M Reck, AS Mansfield, T Mok… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE: IMpower133 (ClinicalTrials. gov identifier: NCT02763579), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed …

NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines

DS Ettinger, DE Wood, C Aggarwal, DL Aisner… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …

NCCN guidelines insights: non–small cell lung cancer, version 5.2018

DS Ettinger, DL Aisner, DE Wood, W Akerley… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the …

[HTML][HTML] First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)

SHI Ou, PA Jänne, TA Leal, II Rybkin… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent
inhibitor of KRAS G12C. We report results from a phase I/IB study of adagrasib in non–small …

[HTML][HTML] Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

ES Kim, V Velcheti, T Mekhail, C Yun, SM Shagan… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …